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infections in these patients requires early diagnosis, differentiation
from other conditions, and the ability to monitor the infection
after treatment. We have developed a real time quantitative PCR
assay for BKV and hereby present data to support its’ clinical
utility. Methods: The forward and reverse primers for our PCR
assay were designed to amplify a conserved region of Agno and
VP-1 genes. Additionally, to monitor the PCR product during the
ampliﬁcation, we designed a TaqMan probe that is complimentary
to the internal region of the ampliﬁed product. The assay has
undergone clinical validation and proﬁciency testing. We tested
our assay on 259 clinical specimens (129 blood, 124 urine, 3 ﬂuid,
1 tissue sample) from 62 BMT patients with hemorrhagic cystitis
for BKV load determination. Results: BKV was detected in 41
patients of the total 62 patients tested. Of the 129 blood samples,
68 tested positive for BKV, the result range is 400-1.9107copies/
ml. Similarly, of the 124 urine samples, 100 tested positive, the
result range is 100-109copies/ml. One BKV-positive patient fol-
lowed serially for hemorrhagic cystitis had persistently high levels
of BK virus in the urine (1.2-1.3109copies/ml) despite clearing
from the blood (with an initial viral load of 1.4106copies/ml).
This 15-year old male with unrelated donor marrow transplant for
treatment of paroxysmal nocturnal hemoglobinuria, had a stormy
post transplant course complicated by severe hemmorhagic cystitis,
aGVHD, and aspergillus and pseudomonas sinusitis. At 140 days
post transplant, he developed pancytopenia and sinopulmonary
disease with a mild ﬂair of hemmorhagic cystitis. No CMV, EBV
or adenovirus could be detected in this patient. However, on
further testing, BKV was found in bone marrow (6.5104 copies/
ml), tracheal aspirate (6.1104 copies/ml), and lung tissue (16
copies/cell) supporting progressive dissemination of the BK virus.
Conclusions: This assay can provide a sensitive, speciﬁc, reliable
and rapid method for diagnosis of life-threatening BKV infection
in BMT patients and would be useful in guiding as well as moni-
toring the response to speciﬁc therapy.
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EMPIRICAL STUDIES ON MOLECULAR FUNGAL DIAGNOSTICS
Manna, P.1, Arnoldi, S.1, Skopec, J.1, Schulenburg, E.1, Umbscheid,
T.1, Caulﬁeld, S.1, Vats, A.2 1. ViraCor Laboratories, Lee’s Summit,
MO; 2. Children’s Hospital of Pittsburgh, Pittsburgh, PA
Introduction: Fungal infections cause signiﬁcant morbidity and
mortality in bone marrow transplants. Despite medical advances, it
is estimated that up to 30% of cases of fungal infections may
remain undiagnosed and untreated at death. Thus, management of
serious fungal infections in these patients requires early diagnosis,
differentiation from other conditions and the ability to monitor the
infection after treatment. Unfortunately, rapid, accurate, sensitive,
and quantitative diagnostics for fungal infections do not exist at this
time. We investigated if quantitative real time PCR technology can
be applied to fungal infections to produce a diagnostic test that can
provide sensitive, accurate, and early detection. Methods: For
fungal genomic DNA isolation, we evaluated 3 commercially avail-
able kits: QIAamp Tissue Kit (Qiagen Inc), MagNA Pure Kit
(Roche Diagnostics), and E. Z. N. A. Fungal DNA Kit (Omega
Bio-tek). We selected 15 different published primer sets and ap-
plied them to both traditional and real time PCR. These primers
were reportedly designed for pan-fungal (PF), pan-Aspergillus (PA)
and pan-Candida (PC) categories. This assay was studied to eval-
uate ampliﬁcation of various Candida (n  4), Aspergillus sp (n  5)
and yeast DNA, both in pure form, in spiked blood, and in a
clinical urine sample. Results: Of the 3 commercially available kits
we evaluated for fungal genomic DNA isolation, our results
showed that the MagNA Pure Kit works better than other kits.
Eleven of the 15 published primer sets could detect fungal ge-
nomes by traditional PCR assay or by the real time assay using
non-speciﬁc SYBR Green dye. Four primer sets (1 PA, 1 PC, 2 PF)
failed to amplify several key fungal strains. Besides, we also iden-
tiﬁed cross ampliﬁcation by several PA and PC primers sets (i.e. PA
primer sets ampliﬁed Candida genomes and vice versa). Conclu-
sion: Developing a single molecular diagnostic assay that can
detect thousands of fungal species is a major challenge. In order to
develop such an assay, we ﬁrst evaluated the published primers.
Our results showed that the majority of them cross-react with
different fungal genera, while several failed to amplify key fungal
genomes—thus giving rise to both false positive and false negative
results. Currently, we are further investigating the development of
fungal assays based on TaqMan and LUX (Light Upon eXtension)
chemistry that would be rapid, sensitive, speciﬁc, and accurate.
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CLINICAL ROLE OF QUANTITATIVE VIRAL LOAD MONITORING FOR
ADENOVIRUS IN IMMUNOCOMPROMISED PATIENTS
Manna, P.1, Vats, A.2, Arnoldi, S.1, Skopec, J.1, Brewer, J.3, Flomen-
berg, P.4 1. ViraCor Laboratories, Kansas City, MO; 2. Children’s
Hospital of Pittsburgh, Pittsburgh, PA; 3. St Luke’s Hospital, Kansas
City, MO; 4. Thomas Jefferson University, Philadelphia, PA
Introduction: Adenovirus (AdV) can cause signiﬁcant morbidity
and mortality in BMT patients. Management of serious AdV in-
fections in these patients requires early diagnosis, differentiation
from other conditions, and the ability to monitor the infection
after treatment. We have developed a quantitative PCR assay for
AdV and hereby present data to support its clinical utility. Meth-
ods: We utilized the real time PCR technique (TaqMan) to quan-
tify AdV DNA in clinical specimens based on the conserved region
of the hexon gene. Additionally, we designed a minor groove-
binding (MGB) label to allow the use of a small oligonucleotide
probe to detect several AdV serotypes. Results: The assay detected
13 of 13 different AdV serotypes. We screened 154 clinical spec-
imens and identiﬁed 5 positive patients. Four positive patients were
monitored serially. Pt #1, with acute GVHD, following bone
marrow transplantation presented with fever, diarrhea and pro-
gressive liver dysfunction. The blood PCR for AdV was positive
and the viral load increased as the liver function worsened (from
5103 copies/ml with AST of 81 to 11103 copies/ml with AST of
198 and progressing to 1.9106 copies/ml with AST of 1061). The
patient died following the peak AdV load of 1.4108copies/ml.
The patient’s liver biopsy by EM found to have particles suggestive
of AdV. Pt #2, with chronic GVHD, on immunosuppressive ther-
apy presented with an acute febrile illness and was found to have an
initial blood AdV load of 5104 copies/ml. He promptly improved
after treatment with high dose IV IgG, with the viral load dropping
to 200 copies/ml. A few weeks later, after a 2nd increase in viral
load (6,200 copies/ml), he was again treated with IV IgG followed
by a decrease in viral load to 200 copies/ml. Four weeks later, after
another dose of IV IgG, the AdV load became undetectable. Pt#3
developed AdV load up to 1.6106copies/ml, did not respond to
IV IgG, but responded promptly to cidofovir with rapid drop in
AdV load and clinical improvement. Unfortunately, Pt#4 with low
AdV load 2103 copies/ml, treated with IV IgG without any
response, then rapidly developed hepatitis and died with very high
AdV load. Conclusions: Use of MGB probe allowed the detection
of multiple AdV serotypes with limited sequence homology. This
assay can provide a rapid method for diagnosis of life-threatening
AdV infection in BMT patients and would be useful in guiding as
well as monitoring the response to speciﬁc therapy.
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VIDEO VISUALIZATION OF THE SMALL BOWEL AIDS IN THE EVALUA-
TION OF INTESTINAL GRAFT VERSUS HOST DISEASE (GVHD)
Morris, J.D., Klooster, M., Condon, D., Zupan, C., Runge, S., Morris,
C.L. Loma Linda University Medical Center, Loma Linda, CA
Endoscopic evaluation for gastrointestinal graft versus host dis-
ease (GvHD) following allogeneic bone marrow transplant (BMT)
is of limited value for detection of distal small bowel disease. Video
visualization was used to evaluate the distal small bowel of a 9 year
old with severe gastrointestinal GvHD following a matched sibling
donor allogeneic BMT. The patient developed severe intestinal
GvHD 30 days after BMT characterized by secretory diarrhea
(1500 cc stool/day) nausea and vomiting. Endoscopy showed ul-
cerations of the duodenum and colon, and biopsies showed histo-
logical ﬁndings of GvHD. The patient was treated with tacrolimus,
methylprednisolone, and ATG. Stool output decreased to 500cc/
day after 3 weeks, but the nausea and abdominal pain persisted.
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Endoscopy showed resolution of GvHD in the colon and duode-
num. Video visualization was performed to evaluate the distal small
bowel using the M2A endoscopic capsule by Given Imaging. The
duodenum and colonic mucosa appeared normal, but the jejunum
and ileum had severe diffuse bleeding ulcerations. The video cap-
sule is 11mm 26mm, weighs less than 4 grams, has a ﬁeld of view
of 140 degrees, and can detect lesions less than 0.1mm. The camera
takes pictures for 8 hours and generates approximately 57,000
images at 2 frames per second. Contraindications include suspected
obstruction or stricture, presence of a cardiac pacemaker, or a
swallowing disorder. Video visualization gives valuable informa-
tion on the status of the distal small bowel that cannot be obtained
by ﬁberoptic endoscopy and may aid in evaluation of GvHD
following allogeneic BMT.
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SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR: ENBREL (ETANER-
CEPT) FOR THE TREATMENT OF IDIOPATHIC PNEUMONIA SYNDROME
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
Yanik, G.A.1, Uberti, J.P.1, Ferrara, J.L.M.1, Levine, J.E.1, Hutchin-
son, R.J.1, Ho, V.T.2, Cooke, K.R.1 1. University of Michigan Medical
Center, Ann Arbor, MI; 2. Dana-Farber Cancer Institute, Boston, MA
Non-infectious lung injury is as a frequent and severe complica-
tion of allogeneic bone marrow transplantation (BMT). In the
acute setting, a diffuse non-infectious process termed Idiopathic
Pneumonia Syndrome (IPS) may occur. Despite advances in sup-
portive care and the use of high dose steroids, mortality from IPS
remains unacceptably high ( 70%). Etanercept is a soluble tumor
necrosis factor (TNF) receptor, consisting of two soluble p75 TNF
receptors fused to the Fc portion of a human IgG1. A trial exam-
ining etanercept in the treatment of IPS following allogeneic
transplant has now been undertaken. Fourteen patients (median 18
yrs, range 1-60 yrs), each meeting the diagnostic criteria for IPS
were treated. Broncho-alveolar lavage (BAL) specimen were ob-
tained pre and post therapy, undergoing analysis for both infec-
tious pathogens (viral, bacterial, fungal, PCP, AFB) and for inﬂam-
matory cytokine markers (TNF, TNFR1, sCD-14, LBP, and
MCP-1). Patients in whom the pre-therapy BAL was positive for a
potential pathogen (by speciﬁc stain or culture) were ineligible for
therapy. Etanercept was administered subcutaneously at a dose of
0.4 mg/kg (maximum dose 25 mg) twice weekly, for a maximum of
8 doses. All patients required supplemental oxygen at therapy
onset, with seven patients requiring mechanical ventilation. Etan-
ercept therapy was initiated a median of 17 days (range 11-87 days)
post transplant. Results: Therapy was well tolerated, with no
infusion related reactions. Eight of 14 patients had a complete
response, deﬁned as the ability to withdraw completely from sup-
plemental oxygen support. In those responding, the median time to
complete response was 7 days (range 3-18 days), and the median
time to normalization of radiographic ﬁndings was 6 days (range
2-10 days). Two other patients had a signiﬁcant reduction in their
FiO2 requirement during therapy. Three patients died while on
therapy, from progressive organ dysfunction. Post therapy BAL
ﬂuid analysis noted a signiﬁcant reductions in all inﬂammatory
cytokines tested, including TNFa, TNFR1, sCD14, LBP and
MCP-1 (Table below). Conclusion: Etanercept therapy was well
tolerated, with minimal toxicity and favorable response in patients
with IPS post allogeneic transplant. The clinical and biochemical
responses seen with therapy support a mechanistic role for TNFa
in the pathogenesis of this disorder. Further trials, investigating the
responsiveness of IPS to etanercept therapy are warranted.
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NEUROLEPTIC MALIGNANT SYNDROME FOLLOWING STEM CELL
TRANSPLANTATION
Craig, M., Ericson, S., Schunn, G., Beall, C.L. Mary Babb Randolph
Cancer Center, West Virginia University, Morgantown, WV
Neuroleptic malignant syndrome (NMS) is a rare disorder pre-
senting with hyperthermia, muscle rigidity, autonomic instability,
and altered consciousness. Although NMS is usually associated
with antipsychotic medications, it has also been described in pa-
tients receiving antiemetics. The estimated incidence in susceptible
populations is about 0.2%, with an associated mortality rate 10-
20%. Three cases of NMS following bone marrow or peripheral
blood stem call transplantation have been described in the medical
literature. We present an additional patient for review. A 51 year-
old female underwent autologous peripheral blood stem cell trans-
plantation for IgA kappa multiple myeloma with high dose mel-
phalan. She achieved engraftment on day 14. Her post-
transplantation course was complicated by persistent nausea and
vomiting requiring treatment with prochlorperazine or prometh-
azine. On day 20, she developed fever of 39.4°C, labile blood
pressure, elevated pulse, and delirium. Antimicrobials were begun
for presumed sepsis. Cultures were negative. By day 21, her
temperature had climbed to 40.9°C, delirium continued, and mus-
cle rigidity developed, with an elevation in CK. She had a gener-
alized tonic-clonic seizure. NMS was diagnosed based on her
clinical scenario and all antiemetics were discontinued. Dantrolene
sodium was initiated IV. Response occurred with resolution of
temperature, decreased muscle rigidity, and improved mental sta-
tus within 24 hours. Previous reports of NMS following transplan-
tation include 2 cases diagnosed 9 and 11 days following autolo-
gous transplantation for liposarcoma and breast cancer (Garrido
SM, et al. Bone Marrow Transplantation 1998;21:427-8). Another
was seen 6 days after allogeneic transplant for AML (Onose M, et
al. Bone Marrow Transplantation 2002;29:803-4). Two had re-
ceived haloperidol, while another received prochlorperazine and
droperidol. All three responded to discontinuing offending medi-
cations and supportive care. There were no deaths. The recogni-
tion of NMS in the post-transplantation setting is confounded by
multiple etiologies for fever and delirium in these patients. The
pathology of the disorder is felt to relate to dopamine blockade.
Initial treatments involve stopping inciting medications and sup-
portive care. Pharmacological interventions such as bromocriptine,
dantrolene sodium, and benzodiazepines should be used to shorten
duration of symptoms and improve survival.
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TACROLIMUS CONVERSION FROM INTRAVENOUS (I.V.) TO ORAL (P.O.)
IN ALLOGENEIC STEM CELL TRANSPLANTATION
Zimmerman, R.L., Petersen, K.A., Hardiman, P.S., Davis, T.L.,
Lynch, J.C., Devetten, M.P. University of Nebraska Medical Center,
Omaha, NE
Tacrolimus (FK506) is commonly used in allogeneic stem cell
transplantation (SCT) to prevent rejection and graft-versus-host
disease. Dosing recommendations are mostly based on studies
performed in solid-organ transplant recipients. The package insert
recommends a conversion rate of 1:4 when changing from the
intravenous to the oral formulation. We retrospectively reviewed
tacrolimus levels and toxicity in 32 patients who underwent allo-
geneic SCT between July 2001 and June 2003 using the package
insert recommended conversion rate. All patients started tacroli-
mus on day -1 at a dose of 0.03 mg/kg actual body weight by
continuous IV infusion. Levels were drawn peripherally on day1,
3, 5 and then biweekly. Target range for tacrolimus levels was
8-12 ng/mL. Conversion from IV to PO at a conversion rate of 1:4
occurred when patients could tolerate P.O. medication. Thirty-
two patients underwent alloSCT for a variety of hematologic
malignancies. Median age at the time of transplant was 43 year
(range 19-58), 78% underwent a MRD donor SCT, 3% a 5/6
MRD SCT, and 19% a MUD SCT, conditioning was Cy/TBI
(89%) or Bu/Cy2 (11%). Ninety-three percent of patients with
available data required at least one IV dose reduction, the median
day of IV to PO conversion was11 (range7-25). The median
Table. BAL Fluid: Mean Values Pre- and Post-Etanercept Therapy
n
TNF
(pg/mL)
TNFR1
(ng/mL)
sCD-14
(ng/mL)
LBP
(ng/mL)
MCP-1
(ng/mL)
Control-A 3 5.2 (0-16) .02 (.02-.03) 0 (0) 0 (0) 0.04 (.015-0.07)
Control-B 10 5.4 (0-23) .11 (.02-.37) 1.9 (0-8.8) 0 (0) 0.28 (0.02-1.0)
IPS pre-Tx 7 93 (0-500) .86 (.08-1.5)* 82.6 (0-250)* 331 (0-1000)* 20 (0.6-73.9)
IPS post-Tx 5 16 (10-23) .18 (.1-0.36)† 3.0 (0-6.2) 0 (0) 0.07 (.05-0.1)†
Controls were (A) a group of healthy volunteers or (B) transplant patients without IPS.
*P .05, IPS pre-tx versus Control-B, †P .05, IPS post-tx versus IPS pre-therapy.
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